Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1089-1100

  Chew, Emily Y ^a   Lovato, James F ^b   Davis, Matthew D ^c   Gerstein, Hertzel C ^d   Danis, Ronald P ^c   Ismail Beigi, Faramarz ^e   Genuth, Saul ^e   Greven, Craig M ^b   Perdue, Letitia H ^b   Cushman, William C ^f   Elam, Marshall B ^f   Thomas Bigger, J ^g   Ginsberg, Henry N ^g   Goff, David C ^h   Ambrosius, Walter T ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Columbia University College of Physicians and Surg ^*  (United States)

^h Global Health and Health Disparities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HEMOGLOBIN A1C; SIMVASTATIN; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DYSLIPIDEMIA; EYE EXAMINATION; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; SIMVASTATIN;

EID: 84975818064     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0024     Document Type: Conference Paper

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sul-phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascu-lar and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
5. Keech AC, Mitchell P, Summanen PA, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697
6. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233-244
7. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
8. Chew EY, Ambrosius WT, Howard LT, et al.; ACCORD Study Group. Rationale, design, and methodsofthe Actionto Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol 2007;99:103i-111i
9. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98(Suppl.):823-833
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
11. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al.; Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
12. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
13. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
14. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015;64:631-642
15. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389
16. Aiello LP, Sun W, Das A, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med 2015;372:1722-1733
17. ACCORD Study Group. 9-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 2016;39: 701-708
18. Chew EY, Davis MD, Danis RP, et al.; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014;121:2443-2451
19. Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 2013; 20:3258-3266
20. Wong TY, Simó R, Mitchell P. Fenofibrate-a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154:6-12
21. Frank RN. Systemic therapies for diabetic retinopathy: the accord eye study. Ophthalmology 2014;121:2295-2296
22. Ferris FL 3rd. How effective are treatments for diabetic retinopathy? JAMA 1993;269:1290-1291
23. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376: 419-430